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Abstract  
Objective: The purpose of this study was to determine if the International 
Hypoglycemia Study Group (IHSG) Level 2 low glucose definition can identify 
clinically relevant hypoglycemia in clinical trials and offer value as an endpoint for 
future trials.  
Research design and methods: A post hoc analysis of the SWITCH (SWITCH 1: 
n=501, type 1 diabetes; SWITCH 2: n=721, type 2 diabetes) and DEVOTE (n=7637, 
type 2 diabetes) trials utilizing the IHSG low glucose definitions. Patients in all trials 
were randomized to either insulin degludec (degludec) or insulin glargine 100 
units/mL (glargine U100). In the main analysis, the following definitions were 
compared: 1) ADA 2005 (plasma glucose [PG] confirmed 3.9 mmol/L with 
symptoms); 2) IHSG Level 2 (glucose confirmed <3.0 mmol/L).   
Results: In SWITCH 2, the estimated rate ratios of hypoglycemic events indicated 
increasing differences between treatments with decreasing PG levels until 3.0 
mmol/L, following which no additional treatment differences were observed. In 
SWITCH 2, the IHSG Level 2 definition produced a rate ratio that was lower than the 
ADA 2005 definition. Similar results were observed for the SWITCH 1 trial.  
Conclusions: The IHSG Level 2 definition was validated in a series of clinical trials, 
demonstrating its ability to discriminate between basal insulins. This definition is 
therefore recommended to be uniformly adopted by regulatory bodies and used in 
future clinical trials. 
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Currently, the definition of hypoglycemia differs between regulatory bodies as well as 
across clinical trials (1±7). For example, hypoglycemia can be defined with or without 
a plasma glucose (PG) value, with or without the presence of symptoms, with a 
requirement for medical assistance (e.g. emergency medical services or 
hospitalization) or by different levels of cognitive dysfunction. This variation in 
K\SRJO\FHPLDGHILQLWLRQVKDVOLPLWHGWKHGLDEHWHVFRPPXQLW\¶VDELOLW\WRFRPSDUHWKH
safety and tolerability of therapies across clinical trials, despite some studies 
investigating a range of hypoglycemia definitions, such as the EDITION trials (7). 
As a result, the International Hypoglycemia Study Group (IHSG), a group of 
clinicians formed to promote greater understanding of the clinical impact of 
hypoglycemia, recently proposed a revised classification of low glucose in diabetes 
(8). The IHSG proposed three definition levels be adopted universally ± Level 1: 
glucose 3.9 mmol/L; Level 2: glucose <3.0 mmol/L; Level 3: severe events requiring 
third party intervention independent of a defined glucose value (9). Of these three, 
the IHSG proposed that the Level 2 definition should be added to current 
classifications as a level sufficiently low to indicate clinically significant 
hypoglycemia. This proposal has subsequently been accepted and adopted by the 
American Diabetes Association (ADA), European Association for the Study of 
Diabetes (EASD) and other organizations including, importantly, the European 
Medicines Agency (EMA) (8,10,11). The IHSG Level 2 definition was based on 
evidence derived from experimental pathophysiological studies and small clinical 
trials, but has not been applied to larger-scale clinical trial data involving patients 
with type 2 diabetes (8). The aim of the present study was to validate the IHSG Level 
2 definition by applying it to a series of clinical trials in patients with type 1 or type 2 
diabetes, investigate the clinical relevance of hypoglycemia defined with a low 
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glucose cut-off, and demonstrate the utility of the IHSG Level 2 definition in the 
conduct of future clinical trials of basal insulins. 
 
Research design and methods 
To apply the IHSG low glucose definitions, data from three double-blind, basal 
insulin comparator trials (SWITCH trials [ClinicalTrials.gov numbers NCT02030600 
{SWITCH 2, type 2 diabetes} and NCT02034513 {SWITCH 1, type 1 diabetes} 
(12,13)]; DEVOTE cardiovascular outcomes trial [ClinicalTrials.gov number 
NCT01959529 {type 2 diabetes} (14,15)]) were utilized. These trials were all 
conducted in accordance with the Declaration of Helsinki and ICH Good Clinical 
Practice Guideline (16,17), and detailed accounts of their trial designs, methods and 
primary results have been published previously (12±15). A summary of these trials is 
included in Supplementary Table 1.  
The purpose of this study was to apply the IHSG low glucose definitions to the 
SWITCH and DEVOTE trials. A summary of the definitions used in this analysis can 
be found in Supplementary Table 2. The IHSG considered glucose concentrations 
detected by self-/laboratory-measured plasma glucose or continuous glucose 
monLWRULQJ+HUHZHXVHWKH,+6*WHUPLQRORJ\RIµJOXFRVH¶ZKHWKHUIURPFDSLOODU\
venous, arterial or interstitial fluid sample measurements. Briefly, the IHSG Level 2 
(confirmed events <3.0 mmol/L (8)) and IHSG Level 3 (events requiring third-party 
assistance (8,9)) definitions were applied to the trial data. For additional comparison, 
the ADA 2005 definition (a PG of 3.9 mmol/L with symptoms (18)) and the Novo 
Nordisk definition (a PG of <3.1 mmol/L with symptoms plus severe events [events 
requiring third-party assistance] (12,13)) were also included. Due to the DEVOTE 
trial design, only the IHSG Level 3 hypoglycemia definition was assessed in this trial.  
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In view of the double-blind, cross-over design of the SWITCH trials and increasing 
attention on hypoglycemia as an important consideration in type 2 diabetes 
management, the focus of this analysis was on the SWITCH 2 (type 2 diabetes) trial 
results. Results from the SWITCH 1 (type 1 diabetes) trial can be found in the 
Supplementary appendix and the severe hypoglycemia (IHSG Level 3) results from 
DEVOTE are included in Figure 4. 
Statistical analyses 
Due to the cross-over design of the SWITCH trials, hypoglycemia was analyzed with 
a Poisson model with patients as a random effect comparing insulin degludec 
(degludec) with insulin glargine 100 units/mL (glargine U100). The DEVOTE trial 
analyzed hypoglycemia using a negative binomial-regression model comparing 
degludec with glargine U100.  
The frequency of hypoglycemic events was assessed by PG levels within the range 
of 2.0±3.9 mmol/L on a pooled randomized treatment dataset. The hypoglycemia 
rate ratios (degludec versus glargine U100) were assessed by glucose levels within 
the same range. This range was selected to encompass the full extent of the ADA 
2005 and IHSG Level 2 definitions while taking into consideration the low number of 
hypoglycemic events that occur below 2.0 mmol/L. 
 
Results 
In SWITCH 1 and 2, the rate of non-severe hypoglycemic events (both symptomatic 
and combined asymptomatic/symptomatic events) increased from 3.0 to 3.9 mmol/L 
with a greater number of events at PG levels approaching 3.9 mmol/L versus PG 
levels approaching 3.0 mmol/L (Figure 1). Similar rates of hypoglycemic events 
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were seen for the total treatment period and after 16 weeks of titration (the 
maintenance period) (Figure 1 and Supplementary Figure S1).  
In SWITCH 1 and 2, the estimated rate ratios of hypoglycemic events comparing two 
basal insulins decreased with decreasing glucose cut-off levels until 3.0 mmol/L, 
indicating greater divergence between the basal insulins with respect to 
hypoglycemic risk (Figure 2). Thereafter, a plateau was reached and the differences 
between the two insulins did not increase any further. A similar result was seen for 
both the maintenance and total treatment periods (Figure 2 and Supplementary 
Figure S2). It is important to note that the confidence intervals widen at the lower 
glucose levels due to the fewer number of events as illustrated in Figure 1 and 
Supplementary Figure S1. This is reflected by the upper confidence intervals, 
which in SWITCH 2 cross the rate ratio of 1 at approximately 2.7 mmol/L and in 
SWITCH 1 at approximately 2.5 mmol/L (Figure 2). In addition, the differences 
between treatments in terms of reduction in hypoglycemia increased, represented by 
the lower estimated rate ratios at each glucose level, when asymptomatic events 
were excluded (Figure 2). Lastly, minimal differences in the rate ratios were 
observed between the 3.0 mmol/L and the 3.1 mmol/L cut-offs.  
Figure 3 shows that symptoms were reported for 70±80% of non-severe 
hypoglycemic events with glucose levels <3.0 mmol/L while decreasing to 
approximately 40% for those events with glucose levels at 3.9 mmol/L. 
In SWITCH 2, the IHSG Level 2 definition produced a rate ratio of 0.76 [0.67; 
0.86]95% CI for degludec versus glargine U100, which is in line with the point 
estimates utilizing the the pre-specified Novo Nordisk hypoglycemia definition 
(Figure 4). Compared with the ADA 2005 definition, the differences between the 
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insulins increased with the IHSG Level 2 and Novo Nordisk definitions although the 
rate ratios for the Novo Nordisk definition were lower, as this definition included 
confirmed symptomatic events only (Figure 4). Comparable results across the 
definitions were observed for the maintenance and total treatment periods.  
In terms of severe hypoglycemia (IHSG Level 3), there was a similarly lower rate 
ratio of hypoglycemia with degludec versus glargine U100 for both treatment periods 
and also for the larger and longer trial, DEVOTE, where the confidence intervals 
were narrower due to the larger number of events (Figure 4). The rate ratios of 
hypoglycemic events for the SWITCH 1 trial can be seen in Supplementary Figure 
S3.  
 
Conclusions 
The results from this analysis provide external validation for the IHSG Level 2 
definition by demonstrating that this definition could identify greater differences 
between two different basal insulins in patients with type 1 or type 2 diabetes 
compared with the ADA 2005 definition. The limited power to identify differences 
between two basal insulins recorded at blood glucose levels above 3.0 mmol/L 
supports WKH,+6*¶VUHFRPPHQGDWLRQVWKDWHYHQWVbetween 3.0 and 3.9 mmol/L 
(Level 1), while serving as an alert value, do not necessarily need to be reported as 
the primary outcome in clinical trials. However, while the discriminatory power 
between treatments at glucose levels between 3.1 and 3.9 mmol/L is limited and 
arguably, less clinically relevant, it may be pertinent for these events still to be 
recorded, perhaps as secondary outcomes, given the importance to patients of 
needing to deal with such episodes. This would ensure that events most critical for 
the ongoing health of patients (<3.0 mmol/L) are recorded and allow for accurate 
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comparisons between treatments, while still recording those events at higher glucose 
levels ( mmol/L). It seems likely, that our understanding of the consequences of 
particular glucose levels will evolve as more trials begin to include continuous 
glucose monitoring that can assess the full range of glucose levels over 24 hours. 
An additional observation from this analysis was that the rate ratios of hypoglycemia 
change across a range of PG values. This highlights the need for the same glucose 
definitions to be used across clinical trials as different results can be obtained 
depending on the definition. Furthermore, applying the IHSG Level 2 definition did 
not change the previous conclusions from the SWITCH trials. Therefore, we 
acknowledge that while the differences between 3.0 and 3.1 mmol/L are negligible, 
as might be expected, our study supports the importance of the IHSG Level 2 
definition (glucose <3.0 mmol/L) for consistency across clinical trials.  
Lastly, the requirement to identify symptoms associated with a hypoglycemic event is 
not essential to be able to differentiate between treatments, particularly since 
thresholds for symptoms can vary between individuals as well as within the same 
individual on different occasions. In the present analysis, the power to differentiate 
between basal insulins increased when only symptomatic events were included 
(Novo Nordisk definition). This is pertinent to the Food and Drug Administration 
(FDA) definition of hypoglycemia that currently stipulates that an event should be 
associated with symptoms and have a PG level <3.9 mmol/L (19). However, 
asymptomatic events should not be overlooked; arguably they are more clinically 
relevant as they lead to cognitive impairment, reduced hypoglycemia awareness and 
are associated with cardiac arrhythmias (18,20±22). Therefore, we would argue that 
in future clinical trials, both events with and without symptoms are recorded, but with 
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the knowledge that excluding asymptomatic events may further highlight the 
differences between interventions, at least in the case of basal insulins. 
Removing the confounding element of different hypoglycemia definitions will add 
power to future analyses of treatments across clinical trials. By also focusing on 
those events with a lower glucose, trials can highlight clinically important events 
while excluding events at higher glucose levels that may be less clinically relevant. 
The ADA, EASD and EMA have already taken the step to incorporate the IHSG 
definitions in their guidance documents (8,10,11). To ensure that clinicians are 
aligned globally we hope that the FDA and other regulatory bodies will consider 
incorporating these definitions in an updated guidance. It will also be important for 
pharmaceutical companies to take steps to align the definitions of hypoglycemia in 
their clinical trials. Furthermore, it could be pertinent for companies to analyze their 
data retrospectively with the IHSG Level 2 definition so that new meta-analyses 
across trials can be conducted.  
The current analysis has a number of limitations. DEVOTE only collected severe 
hypoglycemic events (IHSG Level 3), thereby limiting comparisons with the other 
definitions used in this analysis. However, the point estimate for the relative risk was 
comparable to SWITCH 2 with narrower confidence intervals, emphasizing the 
increased statistical power of a trial with a larger number of events.    
As shown in Figure 2, there was a smaller number of events at lower PG levels, 
reflected by the widening confidence intervals, thereby limiting the interpretation of 
these events. Thus, the choice of a clinically relevant hypoglycemic level to be used 
in clinical trials is a compromise between one which highlights the difference 
between two insulins while retaining sufficient power to demonstrate statistical 
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significance. This is clearly shown in SWITCH 2 (Figure 2) where the rate ratios fall 
to a minimum at PG levels of 2.9±3.0 mmol/L. At PG levels below this, the 
confidence intervals widen, so that at 2.7 mmol/L the rate ratio no longer achieves 
statistical significance. We would argue this justifies the choice of a glucose level 
below 3.0 mmol/L to be used in clinical trials. The differences observed between the 
two basal insulins in SWITCH 1 are less clear-cut, presumably due to the addition of 
bolus insulin that contributed to the total number of hypoglycemic events, but a PG 
level below 3.0 mmol/L appears to be a reasonable compromise. 
Our analysis only extends to clinical trials investigating basal insulins as that was the 
focus of the comparisons in the trials analyzed. Therefore, the applicability of these 
findings to trials comparing other interventions is unknown. Lastly, these trials did not 
include data from continuous glucose monitoring, which is being increasingly 
adopted as a gold standard for hypoglycemia detection with its own 
recommendations for reporting (23).  
This analysis also has a number of strengths including the double-blind trial design 
of the SWITCH and DEVOTE trials and the cross-over design of the SWITCH trials. 
Furthermore, in the SWITCH and DEVOTE trials, individuals with a prior history of 
multiple hypoglycemic events or severe hypoglycemia were not excluded, arguably 
making these trials and our analysis more relevant to patients seen in routine clinical 
practice. In addition, this analysis included a large number of patients across the 
SWITCH and DEVOTE trials as well as a high number of independently adjudicated 
severe hypoglycemic events (Level 3; SWITCH and DEVOTE), emphasizing the 
robustness of this analysis. 
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In conclusion, as the glucose threshold defining hypoglycemic events is decreased, 
fewer events occur. These events are more symptomatic and the discriminatory 
power between two basal insulins increases. Therefore, the results from this analysis 
provide empirical support, based on clinical trials with a double-blind design, for the 
adoption of the IHSG Level 2 definition by regulatory bodies and future clinical trials. 
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Figure 1: Non-severe hypoglycemic events (total and symptomatic) in the 
maintenance period of SWITCH 2 and 1 at different plasma glucose levels in a 
pooled randomized treatment dataset 
 
 
The event rates in the pooled randomized treatment dataset (degludec and glargine U100) 
are plotted at a given plasma glucose level or lower. PYE, patient year of exposure. 
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Figure 2: Estimated rate ratios of non-severe hypoglycemic events (total and 
symptomatic; degludec versus glargine U100) in the maintenance period of 
SWITCH 2 and 1 at different plasma glucose levels 
 
The solid lines represent the estimated rate ratio (degludec versus glargine U100) at 
different plasma glucose levels. The dashed lines represent the upper and lower 95% 
confidence intervals.  Glargine U100, insulin glargine 100 units/mL. 
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Figure 3: Proportion of non-severe hypoglycemic events that were symptomatic in SWITCH 2 at different plasma glucose 
levels 
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Figure 4: Hypoglycemic events in SWITCH 2 and DEVOTE by treatment group 
 
aThe total trial duration was 64 ZHHNVWKLVLQFOXGHGZHHNV¶WUHDWPHQW with once-daily degludec or glargine U100 followed by crossover to 
glargine U100 or degludec, respectively, for a further 32 weeks. Each 32-week treatment period consisted of a 16-week titration period and a 
16-week maintenance period. 
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bPre-specified hypoglycemia definition as used during the original SWITCH 2 and DEVOTE trials.  
cThe median observation time was 1.99 years, and the median exposure time was 1.83 years. 
ADA 2005: plasma glucose 3.9 mmol/L with symptoms; IHSG Level 2: glucose <3.0 mmol/L; IHSG Level 3: severe events requiring third-party 
assistance intervention independent of a defined glucose; Novo Nordisk: plasma glucose <3.1 mmol/L with symptoms plus severe events.  
Glargine U100, insulin glargine 100 units/mL.   
